Intellia Therapeutics, Inc.
NTLA
$9.52
-$2.80-22.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 104.76% | -42.54% | 771.57% | -24.02% | -48.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.76% | -42.54% | 771.57% | -24.02% | -48.82% |
| Cost of Revenue | -19.81% | -3.06% | 7.25% | 8.52% | -12.88% |
| Gross Profit | 29.09% | -10.72% | 6.22% | -12.35% | 8.07% |
| SG&A Expenses | -4.08% | -6.70% | 11.90% | 3.73% | 48.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.90% | -3.85% | 8.22% | 7.53% | 0.05% |
| Operating Income | 20.89% | -5.97% | 2.46% | -10.42% | -5.07% |
| Income Before Tax | 31.11% | -6.42% | 2.47% | -11.04% | -18.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.11% | -6.42% | 2.47% | -11.04% | -18.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.11% | -6.42% | 2.47% | -11.04% | -18.83% |
| EBIT | 20.89% | -5.97% | 2.46% | -10.42% | -5.07% |
| EBITDA | 21.20% | -6.12% | 2.58% | -10.36% | -4.82% |
| EPS Basic | 35.60% | 1.81% | 13.38% | 2.55% | -8.06% |
| Normalized Basic EPS | 24.26% | -2.14% | 15.45% | 4.76% | 6.90% |
| EPS Diluted | 35.60% | 1.81% | 13.38% | 2.55% | -8.06% |
| Normalized Diluted EPS | 24.26% | -2.14% | 15.45% | 4.76% | 6.90% |
| Average Basic Shares Outstanding | 6.97% | 8.37% | 12.60% | 13.94% | 9.97% |
| Average Diluted Shares Outstanding | 6.97% | 8.37% | 12.60% | 13.94% | 9.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |